These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9369265)

  • 21. Vasopressin dilates the rat carotid artery by stimulating V1 receptors.
    Rutschmann B; Evequoz D; Aubert JF; Brunner HR; Waeber B
    J Cardiovasc Pharmacol; 1998 Oct; 32(4):637-41. PubMed ID: 9781933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of AVP.V1-receptor antagonist on urinary albumin excretion and renal hemodynamics in NIDDM nephropathy: role of AVP.V1-receptor.
    Yamada K; Nakano H; Nishimura M; Yoshida S
    J Diabetes Complications; 1995; 9(4):326-9. PubMed ID: 8573758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular effects associated with antidiuretic activity of vasopressin after blockade of its vasoconstrictor action in dehydrated dogs.
    Liard JF
    Circ Res; 1986 May; 58(5):631-40. PubMed ID: 3754791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human internal mammary artery responses to non-peptide vasopressin antagonists.
    Liu JJ; Phillips PA; Burrell LM; Buxton BB; Johnston CI
    Clin Exp Pharmacol Physiol; 1994 Feb; 21(2):121-4. PubMed ID: 8039263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Arg8]vasopressin-induced responses of the human isolated coronary artery: effects of non-peptide receptor antagonists.
    Bax WA; Van der Graaf PH; Stam WB; Bos E; Nisato D; Saxena PR
    Eur J Pharmacol; 1995 Oct; 285(2):199-202. PubMed ID: 8566139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects.
    Burnier M; Fricker AF; Hayoz D; Nussberger J; Brunner HR
    Eur J Clin Pharmacol; 1999 Nov; 55(9):633-7. PubMed ID: 10638391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of receptors mediating contraction of the rat isolated small mesenteric artery and aorta to arginine vasopressin and oxytocin.
    Stam WB; Van der Graaf PH; Saxena PR
    Br J Pharmacol; 1998 Oct; 125(4):865-73. PubMed ID: 9831926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vasopressin(4-9) fragment activates V1a-type vasopressin receptor in rat supraoptic neurones.
    Gouzènes L; Dayanithi G; Moos FC
    Neuroreport; 1999 Jun; 10(8):1735-9. PubMed ID: 10501566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vasodilatory effect of arginine vasopressin is mediated by nitric oxide in human forearm vessels.
    Tagawa T; Imaizumi T; Endo T; Shiramoto M; Hirooka Y; Ando S; Takeshita A
    J Clin Invest; 1993 Sep; 92(3):1483-90. PubMed ID: 8376600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vascular effects of [Arg8]vasopressin in the isolated perfused rat kidney.
    Barthelmebs M; Krieger JP; Grima M; Nisato D; Imbs JL
    Eur J Pharmacol; 1996 Oct; 314(3):325-32. PubMed ID: 8957254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitory effects of SR 49059 on oxytocin-and vasopressin-induced uterine contractions in non-pregnant women.
    Steinwall M; Bossmar T; Gaud C; Akerlund M
    Acta Obstet Gynecol Scand; 2004 Jan; 83(1):12-8. PubMed ID: 14678081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Arginine vasopressin increases renal sodium excretion in the anesthetized rat through V1 receptors.
    Musabayane CT; Forsling ML; Balment RJ
    Ren Fail; 1997 Jan; 19(1):23-32. PubMed ID: 9044449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biphasic forearm vascular responses to intraarterial arginine vasopressin.
    Suzuki S; Takeshita A; Imaizumi T; Hirooka Y; Yoshida M; Ando S; Nakamura M
    J Clin Invest; 1989 Aug; 84(2):427-34. PubMed ID: 2547832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of SR-49059, a vasopressin V1a antagonist, on human vascular smooth muscle cells.
    Serradeil-Le Gal C; Herbert JM; Delisee C; Schaeffer P; Raufaste D; Garcia C; Dol F; Marty E; Maffrand JP; Le Fur G
    Am J Physiol; 1995 Jan; 268(1 Pt 2):H404-10. PubMed ID: 7840290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A nonpeptide vasopressin V(1a) receptor antagonist, SR 49059, does not prevent cisplatin-induced emesis in piglets.
    Grélot L; Girod V; Dapzol J; Maffrand JP; Serradeil-Le Gal C
    Fundam Clin Pharmacol; 2001 Jun; 15(3):189-200. PubMed ID: 11468030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vasopressin and oxytocin: modulators of neurohypophysial blood flow.
    Hurn PD; Wilson DA; Hansen RB; Hanley DF; Traystman RJ
    Am J Physiol; 1993 Dec; 265(6 Pt 2):H2027-35. PubMed ID: 8285241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vasopressin-induced pulmonary vasodilation in rats.
    Walker BR; Haynes J; Wang HL; Voelkel NF
    Am J Physiol; 1989 Aug; 257(2 Pt 2):H415-22. PubMed ID: 2764128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of selective arginine vasopressin V1 and V2 receptor antagonists on burn shock in the rat.
    Sun K; Lin BC; Wang CH; Zhu HN
    Cardiovasc Res; 1991 Apr; 25(4):265-9. PubMed ID: 1884385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of a novel orally effective V1-receptor antagonist, OPC-21268, on AVP-induced sympathoinhibition.
    Masaki H; Imaizumi T; Harada S; Momohara M; Hirooka Y; Takeshita A
    Am J Physiol; 1993 Jun; 264(6 Pt 2):R1089-94. PubMed ID: 8391757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of intra-arterial arginine-vasopressin infusions on peripheral blood flows in conscious dogs.
    Liard JF
    Clin Sci (Lond); 1986 Dec; 71(6):713-21. PubMed ID: 3791873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.